Retatrutide, the investigational triple hormone receptor agonist peptide, represents one of the most closely watched developments in obesity medicine. Developed by Eli Lilly under the compound code LY3437943, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors — a mechanism that distinguishes it from currently approved agents such as semaglutide and tirzepatide. Early Phase 2 trial data have generated significant clinical interest, but retatrutide has not yet received MHRA or EMA authorisation and remains confined to research settings. This article outlines what is currently known about its mechanism, evidence base, safety profile, and regulatory status in the UK.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational once-weekly subcutaneous peptide that activates GLP-1, GIP, and glucagon receptors simultaneously, aiming to suppress appetite and increase energy expenditure beyond the effect of existing approved agents.

Retatrutide (also identified by the compound code LY3437943) is an investigational peptide medicine being developed by Eli Lilly as a potential treatment for obesity and related metabolic conditions. It belongs to a novel class of agents known as triple hormone receptor agonists, meaning it simultaneously activates three distinct receptors involved in appetite regulation and energy metabolism:

• GLP-1 (glucagon-like peptide-1) receptor – reduces appetite and slows gastric emptying

• GIP (glucose-dependent insulinotropic polypeptide) receptor – enhances insulin secretion and, based on preclinical and early clinical evidence, may contribute to improved fat metabolism

• Glucagon receptor – preclinical and early clinical data suggest activation of this receptor may increase energy expenditure and promote fat breakdown (lipolysis), though the precise contribution in humans is still being characterised

This triple-action mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 receptor agonist). By engaging the glucagon receptor alongside GLP-1 and GIP pathways, retatrutide is designed to drive greater caloric expenditure alongside appetite suppression. Whether this translates into meaningfully superior outcomes compared with approved agents can only be established through direct head-to-head trials, which have not yet been conducted.

Retatrutide is administered as a once-weekly subcutaneous injection, similar in delivery to other peptide-based obesity treatments currently available. Its molecular structure has been engineered to extend its half-life, allowing for this convenient weekly dosing schedule. As an investigational compound, it has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and its use remains confined to clinical research settings.

Clinical Trial Evidence and Weight Loss Outcomes

A Phase 2 RCT (NEJM 2023) reported approximately 24% mean body weight reduction at 48 weeks with the 12 mg dose; Phase 3 TRIUMPH trials are ongoing to confirm long-term efficacy and safety.

The most significant clinical data for retatrutide to date comes from a Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023). This trial enrolled adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and evaluated multiple doses of retatrutide against placebo over 48 weeks.

The results were notable. Participants receiving the highest dose (12 mg weekly) achieved a mean body weight reduction of approximately 24% from baseline at 48 weeks — a figure that, whilst encouraging, should be interpreted with caution as cross-trial comparisons with approved agents are not methodologically robust in the absence of head-to-head data. At lower doses, weight reductions ranged from approximately 8% to 17% depending on the dose group. Weight loss appeared to continue throughout the 48-week period, suggesting the potential for further reductions with longer treatment durations, though this requires confirmation in Phase 3 studies. Discontinuation rates due to adverse events were dose-dependent and were driven predominantly by gastrointestinal side effects.

A separate Phase 2 trial also published in The New England Journal of Medicine in 2023 evaluated retatrutide in adults with type 2 diabetes, reporting meaningful reductions in HbA1c alongside weight loss, with hypoglycaemia rates that were low in the absence of insulin or sulfonylurea co-administration.

Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including:

• Reductions in waist circumference

• Improvements in fasting glucose and insulin sensitivity

• Favourable changes in blood pressure and lipid profiles

Phase 3 trials — understood to form part of the TRIUMPH programme — are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease. Active trial registrations can be found on ClinicalTrials.gov by searching for retatrutide or LY3437943. These larger studies will be essential in confirming the long-term efficacy and safety profile of the drug before any regulatory submission can be made. Phase 2 data, whilst promising, does not constitute sufficient evidence for clinical use outside of a research context.

Potential Side Effects and Safety Considerations

The most common side effects are gastrointestinal — nausea, vomiting, and diarrhoea — with additional monitoring warranted for pancreatitis, gallbladder disease, heart rate changes, and diabetic retinopathy.

As with other incretin-based therapies, the most commonly reported adverse effects of retatrutide in clinical trials have been gastrointestinal in nature. These include:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite (which, whilst therapeutically intended, can occasionally be excessive)

• Injection-site reactions (such as redness, bruising, or discomfort at the injection site)

These effects were generally mild to moderate in severity and most frequently occurred during the dose-escalation phase of treatment, tending to diminish over time. Dose-dependent increases in heart rate were also observed, consistent with the glucagon receptor agonism component of the drug, and this warrants careful monitoring in individuals with pre-existing cardiac conditions.

Based on the known class effects of GLP-1 and GIP receptor agonists, the following additional cautions are relevant, even where retatrutide-specific data are still emerging:

• Acute pancreatitis: Participants should be advised to seek urgent medical attention if they develop severe, persistent abdominal pain — particularly pain radiating to the back — accompanied by vomiting, as this may indicate pancreatitis.

• Gallbladder disease: Rapid weight loss is associated with an increased risk of gallstones and cholecystitis. Symptoms such as right upper quadrant pain, fever, or jaundice should prompt prompt medical review.

• Dehydration and acute kidney injury: Gastrointestinal side effects can lead to dehydration, particularly in the early weeks of treatment. Adequate fluid intake should be maintained.

• Hypoglycaemia: Retatrutide itself did not cause significant hypoglycaemia in Phase 2 trials; however, the risk is increased when used alongside insulin or sulfonylureas. Participants in trials who are taking these medicines should have their diabetes regimens reviewed by their clinical team.

• Diabetic retinopathy: Rapid improvement in glycaemic control has been associated with worsening of diabetic retinopathy in trials of other agents in this class. People with pre-existing retinopathy should be monitored appropriately.

• Pregnancy and breastfeeding: Retatrutide is not recommended during pregnancy or breastfeeding. Women of childbearing potential participating in clinical trials are typically required to use effective contraception in accordance with the trial protocol. Anyone who becomes pregnant whilst enrolled in a trial should inform their trial team immediately.

The inclusion of glucagon receptor agonism introduces some additional theoretical considerations compared with dual agonists. Glucagon stimulation can raise blood glucose levels, though the GLP-1 component appears to counterbalance this effect in practice.

Longer-term safety questions — including effects on the pancreas, thyroid, gallbladder, and cardiovascular system — remain under investigation in ongoing Phase 3 trials. Preclinical studies in rodents have identified a potential association between GLP-1 receptor agonists and thyroid C-cell tumours, though there is no confirmed causal link established in humans to date. As a precautionary measure, individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) are typically excluded from trials.

Anyone enrolled in a retatrutide clinical trial who experiences concerning symptoms should contact their trial team promptly. Suspected adverse reactions to medicines — including those received in clinical trials — can also be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Current Regulatory Status in the UK

Retatrutide is not approved by the MHRA or EMA and is unavailable as a licensed medicine in the UK; clinical trial participation via Be Part of Research or ClinicalTrials.gov is the only legitimate access route.

As of the time of writing, retatrutide has not received marketing authorisation in the United Kingdom. It is not approved by the MHRA, nor has it received a positive opinion from the EMA. It is therefore not available as a licensed medicine through the NHS or private prescribing channels in the UK.

The drug is currently progressing through Phase 3 clinical development globally. Should Phase 3 trials demonstrate a favourable benefit-risk profile, Eli Lilly would be expected to submit a Marketing Authorisation Application (MAA) to the MHRA (and separately to the EMA for European markets) for regulatory review. The MHRA operates independently of the EMA following the UK's departure from the European Union, meaning approval timelines and decisions may differ between the UK and EU.

In the UK, NICE (the National Institute for Health and Care Excellence) would subsequently evaluate the clinical and cost-effectiveness of retatrutide before recommending whether it should be made available on the NHS. Given the significant unmet need in obesity management and the weight loss outcomes observed in early trials, there is considerable clinical interest — though formal NICE appraisal remains some years away.

Individuals interested in accessing retatrutide may wish to explore whether they are eligible to participate in ongoing clinical trials. The Be Part of Research portal (bepartofresearch.nihr.ac.uk), run by the NIHR, lists studies recruiting in the UK. The ClinicalTrials.gov database provides international trial listings and can be searched using the term 'retatrutide' or the compound identifier 'LY3437943'. Participation in a clinical trial is the only legitimate route to accessing retatrutide at present, and eligibility criteria apply.

Who May Benefit and What to Discuss with Your GP

Adults with obesity (BMI ≥30 kg/m²) or overweight with weight-related comorbidities are the target population; a GP can review currently licensed options and signpost eligible patients to clinical trials.

Based on the profile of participants enrolled in retatrutide trials to date, the drug appears most relevant to adults living with obesity (BMI ≥30 kg/m²) or those who are overweight (BMI ≥27 kg/m²) with weight-related health conditions such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea. It is worth noting that UK clinical guidance recognises lower BMI thresholds for assessing weight-related health risk in some ethnic groups — your GP or specialist can advise on how this applies to your individual circumstances.

If you are interested in retatrutide or in obesity pharmacotherapy more broadly, a conversation with your GP is an important first step. Your GP can:

• Assess your current weight, BMI, and metabolic health to determine clinical need

• Review existing treatment options that are currently licensed and available in the UK, which may include orlistat, naltrexone/bupropion (Mysimba), semaglutide 2.4 mg (Wegovy — approved by the MHRA for weight management and subject to NICE guidance on eligibility, service setting, and treatment duration), and tirzepatide (Mounjaro — check current MHRA and NICE status at the time of reading, as licensing and commissioning arrangements may have been updated)

• Discuss eligibility for NHS Tier 3 or Tier 4 specialist weight management services, in line with NICE guidance on obesity management, where pharmacotherapy is used as an adjunct to structured lifestyle intervention

• Signpost you to relevant clinical trials via the Be Part of Research portal or ClinicalTrials.gov if you wish to explore participation in retatrutide research

It is important to approach information about investigational medicines with appropriate caution. Whilst the early data for retatrutide is encouraging, it remains a research compound and is not yet proven safe and effective to the standard required for routine clinical use. Purchasing unregulated peptides online — including those marketed as retatrutide — carries serious health risks and is strongly discouraged. The MHRA advises consumers to use only medicines that have been properly authorised and prescribed through legitimate healthcare channels.

Obesity is a complex, chronic condition with significant health consequences, and management should always be guided by a qualified healthcare professional with access to your full medical history.

Frequently Asked Questions